Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients
-
Lina Seiz
Abstract
Several members of the human kallikrein-related peptidase family, including KLK6, are up-regulated in ovarian cancer. High KLK6 mRNA or protein expression, measured by quantitative polymerase chain reaction and enzyme-linked immunoassay, respectively, was previously found to be associated with a shortened overall and progression-free survival (OS and PFS, respectively). In the present study, we aimed at analyzing KLK6 protein expression in ovarian cancer tissue by immunohistochemistry. Using a newly developed monospecific polyclonal antibody, KLK6 immunoexpression was initially evaluated in normal tissues. We observed strong staining in the brain and moderate staining in the kidney, liver, and ovary, whereas the pancreas and the skeletal muscle were unreactive, which is in line with previously published results. Next, both tumor cell- and stromal cell-associated KLK6 immunoexpression were analyzed in tumor tissue specimens of 118 ovarian cancer patients. In multivariate Cox regression analysis, only stromal cell-associated expression, besides the established clinical parameters FIGO stage and residual tumor mass, was found to be statistically significant for OS and PFS [high vs. low KLK6 expression; hazard ratio (HR), 1.92; p=0.017; HR, 1.80; p=0.042, respectively]. These results indicate that KLK6 expressed by stromal cells may considerably contribute to the aggressiveness of ovarian cancer.
©2012 by Walter de Gruyter Berlin Boston
Artikel in diesem Heft
- Guest Editorial
- Highlight: The 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases
- Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance
- Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there
- Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14
- One round of SELEX for the generation of DNA aptamers directed against KLK6
- Kallikrein 6 is a novel molecular trigger of reactive astrogliosis
- Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis
- The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer
- Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients
- The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness
- Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors
- Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14
- Masthead
- Masthead
Artikel in diesem Heft
- Guest Editorial
- Highlight: The 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases
- Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance
- Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there
- Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14
- One round of SELEX for the generation of DNA aptamers directed against KLK6
- Kallikrein 6 is a novel molecular trigger of reactive astrogliosis
- Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis
- The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer
- Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients
- The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness
- Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors
- Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14
- Masthead
- Masthead
